Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study

Therapeutic Advances in Respiratory Disease
Gary J ConnettSaul N Faust

Abstract

Acute viral respiratory illnesses are associated with acquisition of Pseudomonas aeruginosa infection in cystic fibrosis (CF) patients. This study aimed to pilot a protocol for a randomized controlled trial to determine whether oral antipseudomonal antibiotics used at the onset of such episodes might delay onset of infection with this organism. A total of 41 children with CF aged 2-14 years, without chronic Pseudomonas infection, were randomized to receive ciprofloxacin (n = 28) or placebo (n = 13) at the onset of acute viral respiratory infections on an intention to treat basis, during a study period of up to 32 months. There were no unexpected adverse events believed related to the use of the study medication. The rate of withdrawal from the study was low (approximately 7%) and did not differ between groups. Randomization was effective and acceptable to participants. Primary and secondary outcome measures all favoured active treatment, but there were no significant between group differences. The median rate of Pseudomonas isolates was 0/patient/year (interquartile range 0-0.38) in both the active and placebo groups. Kaplan-Meier survival curves showed no significant difference in time to first Pseudomonas isolate between grou...Continue Reading

References

Jan 1, 1989·American Journal of Diseases of Children·K P RamseyI Gonzales-Torres
Sep 24, 2004·American Journal of Respiratory Cell and Molecular Biology·David R KoehlerJim Hu
Oct 7, 2004·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Tim W R LeeJames M Littlewood
Jun 30, 2006·Thorax·B E van EwijkC K van der Ent
May 23, 2007·Pediatric Research·Bart E Van EwijkCornelis K Van der Ent
Oct 27, 2009·Journal of Medical Virology·Angélica M M de VrankrijkerHelle Krogh Johansen
Dec 8, 2009·Chest·Justin R OrtizChristopher H Goss
Mar 25, 2010·BMJ : British Medical Journal·Kenneth F SchulzUNKNOWN CONSORT Group
Aug 14, 2012·Pediatric Pulmonology·Jeffrey S WagenerUNKNOWN Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis

❮ Previous
Next ❯

Citations

Dec 18, 2019·The Cochrane Database of Systematic Reviews·Sally PalserAlan R Smyth
Jul 15, 2016·The Cochrane Database of Systematic Reviews·Tracey RemmingtonChristian Harkensee

❮ Previous
Next ❯

Methods Mentioned

BETA
lavage
enzyme-linked immunosorbent assay
ELISA

Software Mentioned

Stata

Related Concepts

Related Feeds

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.